Cargando…
Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease
The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly. There have recently been publications in the literature regarding the relationship between COVID-19 and Kawasaki disease, but there is no sufficient knowledge about the treatment and follow-up.
Autores principales: | Orbak, Zerrin, Laloglu, Fuat, Akat, Hulya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737124/ https://www.ncbi.nlm.nih.gov/pubmed/33183365 http://dx.doi.org/10.1017/S1047951120004291 |
Ejemplares similares
-
Clinical Features of Children with COVID-19 Infection: Single-Center Experience
por: Guler, Muhammet Akif, et al.
Publicado: (2022) -
Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
por: Wada, Tatsuhiko, et al.
Publicado: (2020) -
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023) -
Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020) -
Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)